PHAGE FUTURES CONGRESS

29-30TH JANUARY 2019 | WASHINGTON D.C, USA

Translating phage-based applications into clinically and commercially viable therapeutics

- **Regulatory guidance** to achieve clinical data from Cara Fiore, FDA
- **Strategies to access the market** via the veterinary, personalized medicine and traditional pharmaceutical routes
- **Insights into investment drivers** for phage therapy from NIH and Merck
- **Facts on how to manufacture GMP phage**
- **Applications to overcome multi-drug resistance** with combined approaches such as phage therapy and antibiotics

SPEAKERS TO INCLUDE:

- Steffanie Strathdee & Tom Patterson
  University of California San Diego
- Carl Merril
  CSO and Founder
  Adaptive Phage Therapeutics
- Martha Clokie
  Professor of Microbiology
  University of Leicester
- Biswajit Biswas
  Chief, Division of Bacteriophage Science, Biological Defense Research Directorate
  US Naval Medical Research Center
- Scott Stibitz
  Microbiologist, Center for Biologics Evaluation and Research
  FDA
- Joe Campbell
  Research Resources Project Officer
  NIH (NIAID)

INSTITUTIONS PRESENT INCLUDE:

- NIH
- FDA
- Adaptive Phage Therapeutics
- AmpliPhi Biosciences Corporation
- Locus Biosciences
- Merck
- UC San Diego
- MIT
- UC San Diego
WELCOME

With antimicrobial resistance an ongoing worldwide issue, there is now a renewed interest in phage therapy as an alternative to antibiotics. There has been uncertainty as to whether phage therapy can be a commercially viable and FDA/EMA approved product. However, the highly positive results of compassionate use cases since 2016 and knowledge gained recently from microbiome research have been key catalysts to progress the field within western medicine. Successful phase II clinical trials are on the horizon!

The Phage Futures Congress will bring together peers from biotech companies and academia, along with experts from regulatory bodies, pharmaceutical companies and government institutions, to discuss how to actively progress clinical science and viable phage application routes to market. The conference will cover key industry trends including:

- Regulatory guidance to achieve clinical data and market approval
- Use of phage in chronic indications such as IBD
- How to manufacture GMP compliant phage
- Opportunities within the personalized medicine model and veterinary market
- Combined therapy approach of phage and antibiotics to alleviate MDR
- Investment drivers

The Phage Futures Congress has the potential to act as a catalyst to further cooperative and collaborative efforts to develop alternate Phage based approaches to the antibiotic crisis.

In addition, the location in the Washington DC area will facilitate an opportunity for Government Agencies, responsible for public health, such as the NIH, FDA, USDA and DOD to participate and interact with educational research groups and biotechnology companies developing phage therapies and initiating clinical testing.

Carl Merril, Adaptive Phage Therapeutics
THE ROADMAP TO COMMERCIAL PHAGE THERAPY MEDICINE

SCIENCE
What does the sequencing of the microbiome mean for phage therapy?
Nick Conley, Locus Biosciences – offering insights into utilising bacteriophages to deliver precision microbiome engineering to eradicate bacterial targets.

IMPLEMENTATION
Translational skills are crucial for progressing phage in human health.
Magda Barbu, C3J Therapeutics – Sharing how to transfer drug development knowledge to phage therapy clinical studies.

REGULATION
What are the phage therapy regulatory considerations for clinical studies
Cara Fiore, FDA – on the required regulatory input for phage, INDs and compassionate case long term validity.

DELIVERY
Antibiotics have a broad spectrum, how can phages compete?
Kevin Yehl, MIT – presenting the importance of engineered phage and next-generation scaffolds to efficiently broaden host range and suppress MDR

APPLICATION
Route to market in phage involves many parameters including disease, host and phage source selections.
Biswajit Biswas, Naval Medical Research Center - discussing a route to market, personalised medicine model and the importance of phage synergy for maximum efficacy.

COLLABORATION
Infectious disease groups with pharma are watching the phage field.
Joe Campbell, NIH – presenting the importance of collaboration and investment in phage therapy to facilitate successful bacteriophage efficacy trials.
ANSWERING THE CRITICAL QUESTIONS TO BUILD A PHAGE FUTURE
TALK TO OUR SPEAKERS ABOUT...

- Addressing future antimicrobial resistance with phage evolution
- Key translational skills
- The applications of phage therapy
- How to produce GMP compliant phage
- The key considerations for designing clinical trials
- Benefits of expanded access cases versus a full clinical trial
- How microbiome related applications are opening up the field
- How to target an appropriate host range
- Why phage therapy is important for industry & where they see it going
- Commercial pathways for phage therapies

www.phage-futures.com | +44 (0)20 3696 2920 | events@kisacoresearch.com

MEDIA PARTNERS
AGENDA DAY 1

PLENARY SESSION: CURRENT OUTLOOK

8:50 am
Chairperson’s opening remarks

9:00 am
KEYNOTE: The success of phage therapy in the US: A patient’s view of receiving phage therapy
- Hear the sequence of events which saved Tom Patterson’s life from a multi-drug resistant bacterial infection
- Gain a patient’s perspective on receiving phage therapy
Professor Thomas Patterson, University of California San Diego
Dr Steffanie Strathdee, Associate Dean of Global Health Sciences, University of California San Diego

9:30 am
KEYNOTE: The evolutionary necessity for the development and uses of phage libraries for the individualized therapy of bacterial infections
- Explore how bacteria, phage and humans evolve and how their subsequent interactions affect the potential use of phage as a therapeutic antibacterial agent
- Address the need for ever expanding clinically relevant and safe phage libraries, touching upon methods to rapidly screen such libraries for effective phage based therapeutic applications
Dr Carl Merril, CSO and Founder, Adaptive Phage Therapeutics

10:00 am
KEYNOTE: Rational analysis of why phase II clinical trials have been failing
- Discuss the science and structure of past clinical trials, including an in-depth view of previous trials such as Nestle and Phagoburn trials
- Explore what was different for the successful Biocontrol efficacy trial
Dr Shawna McCallin, Project Leader, PhageForward

10:30 am
KEYNOTE: Regulatory and manufacturing compliance of phage therapy products
- From a pharmaceutical classification point of view, phages fall in the categories of anti-infectious products and of biological products, given the intended use and their live nature. At the production steps, the compliance to the Good Manufacturing Practices (GMP) is a requirement for any medicinal product, with the objective to ensure the quality, safety and efficacy of both investigational and approved drugs.
- The EU-funded PhagoBurn’s project was conducted with the objective to set the standards from the regulatory and manufacturing points of view. This experience and other projects with natural and genetically modified phages open the way for future developments of phage therapy
Dr Laurent Bretaudeau, Head of R&D, Clean Cells

NETWORKING BREAK

DEVELOPING PHAGE THERAPIES TO MINIMIZE ANTIMICROBIAL RESISTANCE

11:00 am
Combining bacteriophages and antibiotics for wound infections
- Assess the feasibility and efficacy of locally delivering a phage and antibiotic combination (PAC) therapy to treat polymicrobial wound infections
- Present case studies detailing how to develop reproducible infected rat models to test the efficacy of antimicrobials, which rely on non-invasive monitoring techniques to allow the infection to be tracked in ‘real-time’
- Determine if a combination of phage and antibiotic is more effective at reducing the bacterial load of S. aureus compared to either individual treatment in vitro on biofilms
- Develop novel ways to locally deliver antimicrobials to the infected site and reduce undesirable side effects.
Dr Catherine Loc-Carrillo, Internal Medicine, University of Utah
The importance of phage evolution: phage therapy in three cases of MDR Pseudomonas aeruginosa infection

- Present case studies detailing three distinct trials of MDR Pseudomonas aeruginosa infection: 1. a contaminated prosthetic graft; 2. a lung infection associated with cystic fibrosis; and, 3. a lung abscess following radiation therapy.
- Explain the clinical course of the cases and approach to phage therapy with the findings that suggest clinical application of phage can be highly effective at eradication and/or re-sensitization of P. aeruginosa to antibiotics

Dr Benjamin Chan, Yale University

Sequence-specific antimicrobials: CRISPR-Cas delivery via engineered phages

- Discuss engineering the broad host range of phage capsids which demonstrating targeted killing of pathogenic gut bacterial strains and efficient packaging of large DNA circuits in phage capsids

Xavier Duportet, CEO, Eligo Biosciences

The assembly of intestinal bacteriophage communities during inflammation

- Explore how phages associate with the intestinal mucosa and phage abundances are altered during inflammatory bowel disease (IBD)
- Assess how experimental murine colitis, characterized by inflammation of the colon, promotes stochastic changes in the phage community that reflect dysbiosis
- Discuss how murine colitis serves as a model to better understand the role of phages during human IBD

Dr Breck Duerkop, Assistant Professor of Immunology & Microbiology, University of Colorado

Moving from vitro to vivo: Key characteristics and maximising efficacy by optimising the bacteriophage depth

- Discuss C. difficile-phage interactions in biofilm, insect, epithelial cell lines and artificial gut models
- Explore C. difficile adsorption, tail fibers, and resistance

Professor Martha Clokie, Professor of Microbiology, University of Leicester
**AGENDA DAY 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
<th>Speaker</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:50 pm</td>
<td><strong>Precision microbiome engineering with CRISPR-weaponized phages</strong></td>
<td>Discover how weaponizing phages with CRISPR/Cas3 and integrating high-throughput automation, next-generation sequencing, and machine learning can bridge the gap at producing a scalable phage drug product that fits within the pharma paradigm.</td>
<td>Dr Nick Conley, Principal Scientist, Locus Biosciences</td>
<td>Locus Biosciences</td>
</tr>
<tr>
<td>3:15 pm</td>
<td><strong>Importance of understanding phage-host interactions under potential treatment conditions in selecting therapeutic phages</strong></td>
<td>Choose a suitable breadth of phage to effectively eradicate target pathogens.</td>
<td>Dr Betty Kutter, Head of Bacteriophage Lab, Evergreen State College</td>
<td>Evergreen State College</td>
</tr>
<tr>
<td>3:40 pm</td>
<td><strong>Networking Break &amp; Poster Session</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:10 pm</td>
<td><strong>Plenary Session: Routes to Market</strong></td>
<td><strong>KEYNOTE: Utilizing Bacteriophages to Prevent Infections</strong></td>
<td>Dr Mark Engel, CEO, Phagelux</td>
<td>Phagelux</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Commercial realities of therapies vs. preventatives</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Phagelux Solutions: Sustained release sprays and patches</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pricing of Phagelux Solutions and Projected Use of the Products</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>KEYNOTE: Personalized medicine model: The benefits and science considerations in expanded access cases.</strong></td>
<td>Dr Biswajit Biswas, Chief, Division of Bacteriophage Science, Biological Defense Research Directorate, US Naval Medical Research Center</td>
<td>US Naval Medical Research Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Discuss the parameters and practicalities for developing effective phage library to overcome phage resistant bacteria during phage therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:40 pm</td>
<td><strong>Plenary Session: Routes to Market</strong></td>
<td><strong>KEYNOTE: Toward phage clinical trials for emerging markets</strong></td>
<td>Dr Tobi Nagel, Founder &amp; President, Phages for Global Health</td>
<td>Phages for Global Health</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Since approximately 90% of the expected AMR deaths will occur in the developing world, these countries represent significant emerging markets for future phage products</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Details of projects in the developing world that suggests there is an openness to pursuing phage research and regulatory approval in those countries</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:10 pm</td>
<td><strong>Plenary Session: Routes to Market</strong></td>
<td><strong>KEYNOTE: Commercial viability of precision phage therapy</strong></td>
<td>Greg Merril, CEO and Founder, Adaptive Phage Therapeutics</td>
<td>Adaptive Phage Therapeutics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Assess phage library manufacturing and regulatory considerations such as high through-put phage-bacteria matching assays</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Explain efforts to reduce the time needed to deliver a precision targeted phage therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Explore future opportunities for phage therapy as 2nd and 1st line anti-infective agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:40 pm</td>
<td><strong>Plenary Session: Routes to Market</strong></td>
<td><strong>Closing remarks</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:10 pm</td>
<td><strong>Plenary Session: Routes to Market</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:15 pm</td>
<td><strong>END OF DAY ONE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
AGENDA DAY 2

8:00 am REGISTRATION OPENS

PLENARY SESSION: COLLABORATION AND INVESTMENT

8:50 am Chairperson’s Opening remarks

9:00 am KEYNOTE: Encouraging investment: NIAID perspective on and support for bacteriophage therapy

- Learn about the DMID/NIAID pre-clinical services are used to explore the efficacy of bacteriophages in vivo and in vitro
- Details of biopharmaceutical products therapeutic development services-task orders are used to craft product development plans
- Discover how DMID/NIAID genomic services are used to analyse bacteriophage genomes.
- Details of funding of solicited and un-solicited grants to explore and develop the therapeutic bacteriophages and their gene products

Dr Joe Campbell, Research Resources Project Officer, NIH

9:30 am KEYNOTE: Big Pharma View on the clinical utility and commercial opportunity for Phage therapy

- From a big pharma perspective, having clear clinical, regulatory, and commercial paths are paramount to bringing a phage-based product forward
- Discuss the main challenges including narrow-spectrum activity, incomplete host range coverage within a species, and the ability to design appropriate and efficient clinical trials.
- Defining the optimal means to utilize phage therapy to address AMR beyond compassionate care will be vital to derive an ultimate target product profile and value proposition in respect to risk/benefit profiles for the patient.

Dr Carl Balibar, Principal Scientist, Merck

10:00 am KEYNOTE: Obtaining phage therapy pharmacokinetic data via radiolabelled phage

- Discuss the advantages of using radiolabelling for addressing pharmacokinetics regulatory requirements: phage-patient or phage-model organism interactions
- Details of radiolabelling imaging/BioD data from multiple routes of administration (IV, IP, aerosol)
- Assess the practical considerations associated with phage radiolabelling

Dr Derek Holman, Stanford university

10:30 am NETWORKING BREAK

11:00 am PANEL: Clinical trial vs compassionate use

- Discover the FDA’s position on both approaches in phage therapy
- Asses if there is a business case to commercialise the compassionate use long term
- Debate the benefits and challenges of each model

Panellists: Scott Stibitz, Microbiologist, FDA
Brian Varnum, Chief Development Officer, C3J Therapeutics
David Harper, CEO, Evolution Biotechnologies
Carrie-Lynn Langlais Furr, VP of Regulatory Affairs, AmpliPhi Biosciences
Moderator: Shawna McCallin, Project Leader, PhageForward
AGENDA DAY 2

11:50 am KEYNOTE: Regulatory Considerations in the Development of Bacteriophage for Clinical Use
• The U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review (OVRR) regulates bacteriophage (phage) therapy when used for infectious disease indications.
• Discuss the Investigational New Drug (IND) regulatory review process and phage therapy development for studies under IND. Regulatory considerations for clinical studies and the chemistry, manufacturing and control (CMC) information will be reviewed, which may aid in preparation of an Investigational New Drug Application (IND) that is designed to collect clinical data to support marketing approval in the U.S.

Cara Fiore, Microbiologist, FDA

SESSION 1: APPLICATION ROUTES TO CLINICAL DATA

12:20 pm Effective usage of bacteriophage in industrial poultry farming: Importance of the delivery mechanism
• Discussion of a Bacteriophage cocktail can be effectively delivered in large industrial poultry farms
• Multiple delivery formats can deliver phages in stable and economically attractive ways
• Selection of the delivery format is critical for commercial feasibility of phage-based products

Dr Jarek Dastych, CEO, Proteon Pharmaceuticals

12:50 pm NETWORKING LUNCH

2:00 pm Applying the veterinary model as a route to market
• Discuss how progressing a veterinary therapeutic to market, in the high-value companion animal sector, will provide proof of concept for both regulatory progression and commercialisation, while also providing valuable data on safety and efficacy for phage therapy in general
• Assess field trial data in canine otitis, as then undertaken provided useful data. for progression into clinical trials against otitis in humans but could also lead directly into pre-market trials for a veterinary therapeutic and low-cost model.

Dr David Harper, CEO, Evolution Biotechnologies

2:25 pm Bacteriophage lysins: novel non-traditional antimicrobial treatments for MDR pathogens
• Explore the principles and applications of Lysins which are enzymes capable of cleaving bonds in the peptidoglycan layer of bacterial cell walls, resulting in rapid hypotonic lysis and bacterial death within seconds after contact
• Details of data that supports the resistance to these molecules are orders of magnitude less likely than traditional antibiotics, making lysins an ideal antimicrobial for the treatment of MDR pathogens such as MRSA, Carbapenem resistant Acinetobacter and others

Chandra Ghose, Bioharmony Therapeutics
2:50 pm  **Engineering bacteriophage to combat infectious disease and remodel the microbiome**

- Learn about engineering phage as sequence-specific antimicrobials
- Explore assembling and editing phage genomes using a yeast-based platform and suppressing bacterial resistance through tail fiber mutagenesis
- Discover the next-generation therapeutic phage scaffolds

**Dr Kevin Yehl, Lead Phage Researcher**  
(Timothy’s Lu group), MIT

3:15 pm  **Can bacteriophages improve the microbiome and human health?**

- Assess how the consumption of therapeutic doses of bacteriophages are safe and tolerable in human populations, at least in the short-term
- Explore how bacteriophages may have the ability to influence microbiome-related disease biomarkers (e.g., LDL cholesterol)
- Discuss the future therapeutic utility of bacteriophages may include prophylactic effects against ingested enteric pathogens, which are largely responsible for nutritional deficiencies derived from chronic diarrhoea in the developing world

**Dr Taylor Wallace, George Mason University**

3:40 pm  **NETWORKING BREAK**

5:00 pm  **Commercial Considerations for Implementing Phage Therapy in Western Hospitals: Pricing and Access Implications**

- Therapeutic utilization in the hospital setting is highly influenced by health system access and reimbursement
- Driving access and adoption in this setting is increasingly challenging for innovative therapeutic technology
- Understanding the reimbursement structure, key decision-makers and their incentives will inform commercial strategy and influence value for phage therapeutics

**Kate Kitsopoulos, Partner, Triangle Insights Group**
WHO WILL YOU MEET?

This congress will bring together international delegates and stakeholders across all disciplines related to phage including:

- **Biotechnology companies**
  Build relationships, partner, gain regulatory knowledge and discover recent advancements

- **Pharmaceutical companies**
  Learn about the current applications in phage, innovations from microbiome research and improve current antimicrobial resistance alternatives through collaboration

- **Physicians/clinicians**
  Understand how your patients can benefit from phage in various disease indications, more about the therapy in a clinical setting & how to improve patient outcomes

- **Service Providers**
  Meet the people who need your services, better understand their needs in the context of phage therapy

- **Academics**
  Improve industry know how, build partnerships, collaborate, discuss work

- **Regulatory Bodies**
  Interact and provide regulatory guidance to educational research groups and biotechnology companies developing phage therapies

THE ONSITE EXPERIENCE

Human Biotech & Animal Health, Boston 2018

3rd Annual European Microbiome Congress
BE A PART OF PHAGE FUTURES

POSTER PRESENTATION

Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration).

At the Congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the afternoon networking break on day one.

SUBMISSIONS ARE NOW CLOSED

Poster abstract submission deadline is on 17th December 2018.

Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!

Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

STUDENTS

Phage Futures is calling all students! As the congress looks to the future of phage therapy, we are encouraging young researchers to get involved. Progressing phage therapy is dependent on collaboration and innovative thinking so input from rising stars is key! Join the congress with our special student price, you’ll have the opportunity to:

• Engage with industry as well as academia to expand your network and career opportunities
• Get involved in the debate about approaching the clinic
• Showcase your innovations through the poster session

STUDENT PASSES ARE NOW SOLD OUT
INTERESTED IN SPONSORSHIP OPPORTUNITIES?

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list. With our extensive marketing experience and strategy, your partnership with the conference will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts.

WHY PARTNER?

- Build meaningful connections & grow your network
- Showcase your brand & demonstrate your expertise as a thought leader
- Stay ahead of the competition & increase your market share

A GREAT OPPORTUNITY FOR YOUR:

- Contract Manufacturer Organization
- Contract Research Organization
- Sequencing Technology Company
- Detection Platform Supplier
- Phage Library Supplier

ASK US ABOUT THE DIFFERENT WAYS YOU CAN GET INVOLVED.

Contact our team to find out more about each package by emailing partner@kisacoresearch.com or by calling +44 (0)20 3696 2920

www.phage-futures.com | +44 (0)20 3696 2920 | events@kisacoresearch.com
**Pricing**

<table>
<thead>
<tr>
<th>Category</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard (Pharmaceutical, Large Biotechs &amp; Service Providers)</td>
<td>$2,199</td>
</tr>
<tr>
<td>Small Biotech (Under 30 Employees)</td>
<td>$1,699</td>
</tr>
<tr>
<td>Academic</td>
<td>$899</td>
</tr>
<tr>
<td>Student - SOLD OUT</td>
<td>-</td>
</tr>
</tbody>
</table>

**Big Savings with Big Bookings**

- **Save 10%** Book a team of 3+
- **Save 15%** Book a team of 5+

**Venue & Accommodation**

We’re thrilled to be in Washington D.C, USA for Phage Futures. The Congress will take place at the Hilton McLean Tysons Corner. Please visit [www.phage-futures.com](http://www.phage-futures.com) for venue information and links to accommodation.

**Click Here to Register Online**

Kisaco Research reserves the right to ensure that the correct pricing categories are applied to all registrants. Team discounts are only valid on industry rates and not in conjunction with any other offer or promotion. Payment Terms: Please note that a $79 processing fee will apply to any invoices requested. All Prices are in USD. All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above. No discount offers can be combined with any other offer. Please view our Cancellation Policy. QUESTIONS? Please email events@kisacoresearch.com

[www.phage-futures.com](http://www.phage-futures.com) | +44 (0)20 3696 2920 | events@kisacoresearch.com
JOIN OUR GLOBAL SERIES

NORTH AMERICAN MICROBIOME CONGRESS
North American Microbiome Congress
Washington DC, USA
6-7 February, 2019

ANIMAL MICROBIOME CONGRESS USA
Animal Microbiome Congress USA
19-20 March, 2019

4TH ANNUAL EUROPEAN MICROBIOME CONGRESS
4th Annual Microbiome Congress
London, UK
14-15 November, 2018

ANIMAL HEALTH INVESTMENT EUROPE
Animal Health Investment Europe
London, UK
26-27 February, 2019

WHAT OUR ATTENDEES SAY

‘The event had an adequate mix of topics revolving microbiome, be it from a scientific, commercial or regulatory point of view’
– Eva Mong, Jennewein Biotech

‘Good conference overall, very good talks, nice ambiance for discussions and good contacts made during the two days’
– Cordaillat Simmons, Pharmabiotic

‘Excellent introduction to the needs and opportunities in animal health for the human health world’
– Alan Schneuer, Fairbanks Pharma